drugset / Trial / NCT01874340

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

NCT01874340

Phase 2 Terminated 28 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.

Timeline

Start
2013-06
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody Intravenous

Indications